Cat. # | Size | Qty. | Price |
---|---|---|---|
92570T | 1 Kit (8 x 20 microliters) |
|
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
Phospho-RIP (Ser166) (D1L3S) Rabbit mAb 65746 | 20 µl |
|
H | 78-82 | Rabbit IgG |
RIP (D94C12) XP® Rabbit mAb 3493 | 20 µl |
|
H M R Hm Mk | 78 | Rabbit IgG |
Phospho-MLKL (Ser358) (D6H3V) Rabbit mAb 91689 | 20 µl |
|
H | 54 | Rabbit IgG |
MLKL (D2I6N) Rabbit mAb 14993 | 20 µl |
|
H | 54 | Rabbit IgG |
Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb 9664 | 20 µl |
|
H M R Mk | 17, 19 | Rabbit IgG |
Caspase-3 (D3R6Y) Rabbit mAb 14220 | 20 µl |
|
H M R Mk | 35, 19, 17 | Rabbit IgG |
Cleaved Caspase-8 (Asp384) (11G10) Mouse mAb 9748 | 20 µl |
|
H | 10 | Mouse IgG1 |
Caspase-8 (D35G2) Rabbit mAb 4790 | 20 µl |
|
H M R | 10, 57 | Rabbit IgG |
Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Goat | ||
Anti-mouse IgG, HRP-linked Antibody 7076 | 100 µl |
|
Horse |
Product Information
Monoclonal antibodies are produced by immunizing animals with synthetic peptides surrounding Leu190 of human RIP1, the carboxy terminus of human MLKL and human caspase-8, the amino-terminal sequence of p10 of human caspase-8, amino terminal residues adjacent to Asp175 of human caspase-3, a recombinant protein corresponding to the p20 subunit of caspase-3, and phosphopeptides surrounding human Ser166 of human RIP and Ser358 of human MLKL.
Apoptosis is a regulated physiological process leading to cell death (1,2). Caspases, a family of cysteine acid proteases, are central regulators of apoptosis. Caspases are synthesized as inactive zymogens containing a pro-domain followed by large (p20) and small subunits (p10) that are proteolytically processed in a cascade of caspase activity. Initiator caspases (including 8, 9, 10, and 12) are closely coupled to proapoptotic signals. Once activated, these caspases cleave and activate downstream effector caspases (including 3, 6, and 7), which in turn cleave cytoskeletal and nuclear proteins like PARP, α-fodrin, DFF, and lamin A, and induce apoptosis. Cytochrome c released from mitochondria is coupled to the activation of caspase-9, a key initiator caspase. Apoptosis induced through the extrinsic mechanisms involving death receptors in the tumor necrosis factor receptor superfamily activates caspase-8. Activated caspase-8 cleaves and activates downstream effector caspases, such as caspase-1, -3, -6, and -7. Caspase-3 is a critical executioner of apoptosis, as it is either partially or totally responsible for the proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADP-ribose) polymerase (PARP).
Necroptosis, a regulated pathway for necrotic cell death, is triggered by a number of inflammatory signals, including cytokines in the tumor necrosis factor (TNF) family, pathogen sensors such as toll-like receptors (TLRs), and ischemic injury (3,4). Necroptosis is negatively regulated by caspase-8 mediated apoptosis in which the kinase RIP/RIPK1 is cleaved (5). Furthermore, necroptosis is inhibited by a small molecule inhibitor of RIP, necrostatin-1 (Nec-1) (6). Research studies show that necroptosis contributes to a number of pathological conditions, and Nec-1 has been shown to provide neuroprotection in models such as ischemic brain injury (7). RIP is phosphorylated at several sites within the kinase domain that are sensitive to Nec-1, including Ser14, Ser15, Ser161, and Ser166 (8). Phosphorylation drives association with RIP3, which is required for necroptosis (9-11). Mixed lineage kinase domain-like protein (MLKL) is a pseudokinase that was identified as a downstream target of RIP3 in the necroptosis pathway (12). During necroptosis, RIP3 is phosphorylated at Ser227, which recruits MLKL and leads to its phosphorylation at Thr357 and Ser358 (12). Knockdown of MLKL through multiple mechanisms results in inhibition of necroptosis (13). Phosphorylation of MLKL during necroptosis leads to its oligomerization with pore formation that affects membrane integrity (14-17).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.